IP Library Granted Patent US 9,320,741
Granted Patent B2
US 9,320,741 · App. 14/502,840 · Granted Apr 26, 2016

Compositions and methods for treating neoplasia, inflammatory disease and other disorders

Inventors: James Elliott Bradner (Weston, MA); Jun Qi (Sharon, MA)
Assignee: DANA-FARBER CANCER INSTITUTE, INC.
A61K31/551A61K31/5517C07D487/04C07D495/12C07D495/14C07D519/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,320,741
App. No.
14/502,840
Granted
Apr 26, 2016
Kind
B2
Abstract

The invention features compositions and methods for treating or preventing a neoplasia. More specifically, the invention provides compositions and methods for disrupting the interaction of a BET family polypeptide comprising a bromodomain with chromatin (e.g., disrupting a bromodomain interaction with an acetyl-lysine modification present on a histone N-terminal tail).

Claims (15)

1. A method of treating a condition in a subject in need thereof, the method comprising administering to the subject an effective amount of any one of compounds represented by the following structural formulas

or a pharmaceutically acceptable salt thereof,

wherein the condition is selected from the group consisting of prostate cancer, renal cell carcinoma, hepatoma, lung cancer, breast cancer, colon cancer, neuroblastoma, glial blastoma multiforme, squamous cell carcinoma involving a NUT rearrangement, NUT midline carcinoma and non-small cell lung cancer.

2. The method of claim 1 , wherein the compound is represented by the structural formula

or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 , wherein the compound is represented by the structural formula

or a pharmaceutically acceptable salt thereof.

4. The method of claim 1 , wherein the compound is represented by the structural formula

or a pharmaceutically acceptable salt thereof.

5. The method of claim 1 , wherein the lung cancer is small cell lung cancer.

6. The method of claim 1 , wherein the lung cancer is non-small cell lung cancer.

7. The method of claim 1 , wherein the condition is NUT midline carcinoma.

8. The method of claim 1 , wherein the condition is prostate cancer.

9. The method of claim 1 , wherein the condition is renal cell carcinoma.

10. The method of claim 1 , wherein the condition is hepatoma.

Assignments (2)
CONFIRMATORY LICENSE Recorded Dec 29, 2016
From: DANA-FARBER CANCER INST
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 041210/0200 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 17, 2015
From: BRADNER, JAMES ELLIOTT; QI, JUN
To: DANA-FARBER CANCER INSTITUTE, INC.
Reel/Frame 035009/0388 →
Continuity (6)
Continuation 13698010
Provisional Application 61334991 · May 14, 2010
Provisional Application 61370745 · Aug 4, 2010
Provisional Application 61375863 · Aug 22, 2010
Provisional Application 61467376 · Mar 24, 2011
Related Publication 20150150885A1 · Jun 4, 2015